Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiAscletis's daily acne tablet set for China review after Phase III win
MiRedwire gains Aspera contract for space-based cancer research
MiAgenus and Zydus sign agreements for botensilimab and balstilimab
MiMagazine: Are regulators keeping pace with AI adoption in clinical trials?
MiRoche extends SMA market lead with Evrysdi tablet approval in Europe
MiEC approves Takeda ADC plus chemo for stage IIb Hodgkin's lymphoma
DiASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
DiSpyGlass Pharma secures $75m for ophthalmic drug delivery platform
DiASCO25: Kura's Phase II ziftomenib results trigger NDA acceptance from FDA
DiASCO25: Genmab's Rina-S en route to 'blockbuster potential' amid further positive data
DiFDA grants expanded access to ImmunityBio's Anktiva for lymphopenia
DiRegeneron to acquire rights for Hansoh's HS-20094 therapy
MoBMS outlays $11bn to join BioNTech's development of bispecific cancer drug
MoSanofi to expand immunology offerings with Blueprint Medicines
MoASCO25: J&J's Carvykti shows strong efficacy across multiple myeloma risk groups
MoSanofi and Regeneron report results from two Phase III trials of COPD treatment
MoASCO25: MSD's KRAS G12C drug shows early promise in Phase I
MoASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
MoCirCode Biomed gains clearance from FDA for RNA drug HM2002
MoZymeworks' zanidatamab gains approval in China for biliary tract cancer
FrASCO25: Pfizer's Braftovi combo boasts 47% drop in disease progression in mCRC
FrEyePoint advances with Duravyu Phase III trial
FrAlvotech and Advanz to commercialise biosimilars in Europe
FrFDA rejects Stealth Bio's Barth syndrome treatment after 16.5-month review
FrAstellas and Evopoint sign ADC licensing deal